EVERSANA (Canada)

Recent papers from EVERSANA (Canada)

1. Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studiesJournal of Comparative Effectiveness Research · 2026
2. Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in ItalyAdvances in Therapy · 2026
3. Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting SystemMayo Clinic Proceedings Innovations Quality & Outcomes · 2026
4. Console-Associated Surgical Workflow Performance in Vitreoretinal Surgery: A Comparative Time-and-Motion Study of UNITY VCS and CONSTELLATION Vision SystemsOphthalmology and Therapy · 2026
5. Tardive Dyskinesia in Patients Receiving Continuous Versus Intermittent Oral Metoclopramide: A Retrospective Real World StudyNeurogastroenterology & Motility · 2026
6. Consensus-based recommendation for presbyopia-correcting intraocular lens use and patient selection: a Delphi studyScientific Reports · 2026
7. Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspectiveJournal of Medical Economics · 2026
8. All-cause healthcare cost differences across ambulatory cardiac monitoring modalities in Medicare beneficiaries: a real-world claims-based study using entropy balancingJournal of Medical Economics · 2026
9. Methodological pitfalls in indirect treatment comparisons: insights from a recent systematic review and analysis for C3 glomerulopathyJournal of Comparative Effectiveness Research · 2026
10. A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world dataAnnals of Hematology · 2026
11. The cost-effectiveness of biosimilar denosumab in postmenopausal osteoporosis: implications of baseline fracture risk and drug priceOsteoporosis International · 2026
12. Clinical and Economic Outcomes in Diagnostic-Naïve Medicare Fee-for-Service Beneficiaries Managed with Alert-Based Ambulatory Cardiac Monitors: the CAMELOT-ALERT StudyAmerican Heart Journal · 2026
13. A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2− Advanced/Metastatic Breast Cancer: A Comparison of Real-World EvidenceCancers · 2026
14. Optimizing Patient-Reported Outcomes for HTA Success: Lessons from German Early Benefit AssessmentsAdvances in Therapy · 2026
15. Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene PanelsOncology and Therapy · 2026
16. Benchmark Survey on Content Development and Key Performance Indicators: A phactMI Benchmarking Survey UpdateTherapeutic Innovation & Regulatory Science · 2026
17. Indirect Treatment Comparison of Tezepelumab Versus Other Biologics in Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Literature Review and Network Meta-analysisAdvances in Therapy · 2026
18. Real-world outcomes and subsequent treatment utilization following anti-B-cell maturation antigen antibody-drug conjugate exposure in patients with multiple myeloma.Journal of Clinical Oncology · 2026
19. Modelled CKD benefits of broad SGLT-2i eligibility in the UKKidney International Reports · 2026
20. Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye diseaseJournal of Comparative Effectiveness Research · 2026